FY2025 EPS Estimates for CRISPR Therapeutics AG Lowered by Analyst (NASDAQ:CRSP)

CRISPR Therapeutics AG (NASDAQ:CRSP) – Investment analysts at Brookline Capital Management cut their FY2025 earnings estimates for CRISPR Therapeutics in a research report issued on Wednesday, May 8th. Brookline Capital Management analyst L. Cann now expects that the company will post earnings per share of $5.04 for the year, down from their previous forecast of $5.08. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($6.24) per share. Brookline Capital Management also issued estimates for CRISPR Therapeutics’ FY2026 earnings at $8.56 EPS, FY2027 earnings at $12.48 EPS and FY2028 earnings at $26.51 EPS.

Other analysts have also recently issued reports about the company. Morgan Stanley upped their target price on CRISPR Therapeutics from $46.00 to $48.00 and gave the company an “underweight” rating in a report on Monday, February 26th. Wells Fargo & Company dropped their price target on shares of CRISPR Therapeutics from $70.00 to $65.00 and set an “equal weight” rating for the company in a research note on Thursday. Robert W. Baird upped their price objective on CRISPR Therapeutics from $46.00 to $52.00 and gave the company a “neutral” rating in a report on Thursday. TheStreet raised CRISPR Therapeutics from a “d+” rating to a “c” rating in a research note on Friday, February 23rd. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a research note on Thursday. Three analysts have rated the stock with a sell rating, seven have given a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $74.43.

CRISPR Therapeutics Stock Down 0.1 %

Shares of CRISPR Therapeutics stock traded down $0.03 on Friday, hitting $53.52. 188,567 shares of the company were exchanged, compared to its average volume of 1,742,249. CRISPR Therapeutics has a 1-year low of $37.55 and a 1-year high of $91.10. The stock has a market capitalization of $4.54 billion, a price-to-earnings ratio of -27.32 and a beta of 1.80. The company has a 50-day moving average price of $65.19 and a 200 day moving average price of $64.56.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Wednesday, May 8th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by ($0.08). The firm had revenue of $0.50 million for the quarter, compared to analyst estimates of $25.53 million. The firm’s revenue for the quarter was down 99.5% on a year-over-year basis. During the same quarter last year, the business posted ($0.67) EPS.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,913 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $79.67, for a total transaction of $152,408.71. Following the transaction, the general counsel now owns 57,371 shares in the company, valued at approximately $4,570,747.57. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 2,801 shares of the business’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $78.26, for a total transaction of $219,206.26. Following the completion of the sale, the general counsel now owns 60,070 shares in the company, valued at $4,701,078.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, General Counsel James R. Kasinger sold 1,913 shares of the business’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $79.67, for a total transaction of $152,408.71. Following the sale, the general counsel now owns 57,371 shares of the company’s stock, valued at approximately $4,570,747.57. The disclosure for this sale can be found here. Insiders have sold a total of 83,992 shares of company stock worth $6,132,335 in the last three months. Insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On CRISPR Therapeutics

Several institutional investors have recently bought and sold shares of CRSP. Jump Financial LLC lifted its holdings in CRISPR Therapeutics by 194.7% in the 3rd quarter. Jump Financial LLC now owns 33,307 shares of the company’s stock valued at $1,512,000 after acquiring an additional 22,006 shares during the last quarter. Invesco Ltd. lifted its holdings in CRISPR Therapeutics by 1.5% in the 3rd quarter. Invesco Ltd. now owns 136,123 shares of the company’s stock valued at $6,179,000 after acquiring an additional 2,061 shares during the last quarter. ARK Investment Management LLC lifted its stake in CRISPR Therapeutics by 19.2% during the fourth quarter. ARK Investment Management LLC now owns 8,536,104 shares of the company’s stock valued at $534,360,000 after buying an additional 1,372,986 shares in the last quarter. Prime Capital Investment Advisors LLC purchased a new stake in CRISPR Therapeutics during the fourth quarter valued at about $206,000. Finally, Baker Chad R lifted its stake in CRISPR Therapeutics by 89.1% during the fourth quarter. Baker Chad R now owns 98,520 shares of the company’s stock valued at $6,167,000 after buying an additional 46,420 shares in the last quarter. Institutional investors and hedge funds own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.